Eli Lilly (LLY) Share-based Compensation (2009 - 2026)

Eli Lilly (LLY) has reported Share-based Compensation for 18 consecutive years, with $161.0 million the latest figure, recorded in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $161.0 million, up 4.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $633.0 million (down 1.19% YoY), and the FY2025 annual result was $626.0 million, down 3.1% from the prior year.
• Share-based Compensation was $161.0 million for Q1 2026 at Eli Lilly, up from $136.1 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $215.6 million in Q3 2023 and troughed at $85.1 million in Q3 2022.
• Average Share-based Compensation over 5 years is $143.1 million, with a median of $142.3 million recorded in 2024.
• Year-over-year, Share-based Compensation surged 153.35% in 2023 and slumped 38.22% in 2024.
• Over 5 years, Share-based Compensation stood at $92.9 million in 2022, then rose by 29.92% to $120.7 million in 2023, then increased by 17.9% to $142.3 million in 2024, then fell by 4.36% to $136.1 million in 2025, then rose by 18.3% to $161.0 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $161.0 million in Q1 2026, $136.1 million in Q4 2025, and $151.1 million in Q3 2025.